{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:09:26Z","timestamp":1790071766185,"version":"4.0.1"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T00:00:00Z","timestamp":1339459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Although guidelines recommend use of oral 5\u2010aminosalicylates (5\u2010<jats:styled-content style=\"fixed-case\">ASA<\/jats:styled-content>s) as first\u2010line therapy in patients with mild to moderate ulcerative colitis (<jats:styled-content style=\"fixed-case\">UC<\/jats:styled-content>) and ulcerative proctitis (<jats:styled-content style=\"fixed-case\">UP<\/jats:styled-content>) and steroids with or without 5\u2010<jats:styled-content style=\"fixed-case\">ASA<\/jats:styled-content>s in those more severely ill, little is known about how <jats:styled-content style=\"fixed-case\">UC<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">UP<\/jats:styled-content> are actually treated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To document treatment of new\u2010onset <jats:styled-content style=\"fixed-case\">UC<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">UP<\/jats:styled-content> in routine clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using a large <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content> health insurance database, we identified all persons with new\u2010onset <jats:styled-content style=\"fixed-case\">UC<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">UP<\/jats:styled-content> between 1 <jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>anuary 2005 and 31 <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>ecember 2007, based on: (i) initial receipt of an oral 5\u2013<jats:styled-content style=\"fixed-case\">ASA<\/jats:styled-content>, mesalazine (mesalamine) suppository, 5\u2010<jats:styled-content style=\"fixed-case\">ASA<\/jats:styled-content> enema, steroid, antimetabolite, budesonide or <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> inhibitor; (ii) sigmoidoscopy\/colonoscopy in prior 30\u00a0days resulting in a new diagnosis of <jats:styled-content style=\"fixed-case\">UC<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">UP<\/jats:styled-content> and (iii) no prior encounters for <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>rohn's disease. We examined patterns of pharmacotherapy over 1\u00a0year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 1516 <jats:styled-content style=\"fixed-case\">UC<\/jats:styled-content> patients and 636 <jats:styled-content style=\"fixed-case\">UP<\/jats:styled-content> patients who met study entry criteria. In <jats:styled-content style=\"fixed-case\">UC<\/jats:styled-content>, initial therapies most frequently used were oral 5\u2010<jats:styled-content style=\"fixed-case\">ASA<\/jats:styled-content>s (53% of patients), oral 5\u2010<jats:styled-content style=\"fixed-case\">ASA<\/jats:styled-content>s and systemic steroids (12%), systemic steroids (8%) and mesalazine suppositories (6%); in <jats:styled-content style=\"fixed-case\">UP<\/jats:styled-content>, mesalazine suppositories (42%) and oral 5\u2010<jats:styled-content style=\"fixed-case\">ASA<\/jats:styled-content>s (19%) were most often used, followed by combination therapy (14%), mesalazine enema\u00a0(11%) and rectal steroids (10%). Few patients received maintenance therapy, and there was limited use of antimetabolites and biological agents.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Oral 5\u2010<jats:styled-content style=\"fixed-case\">ASA<\/jats:styled-content>s and systemic steroids are the mainstay of treatment in patients with new\u2010onset <jats:styled-content style=\"fixed-case\">ulcerative colitis<\/jats:styled-content>; in those with new\u2010onset <jats:styled-content style=\"fixed-case\">ulcerative proctitis<\/jats:styled-content>, it is mesalazine suppositories. Care of these patients appears consistent with treatment guidelines.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2012.05175.x","type":"journal-article","created":{"date-parts":[[2012,6,13]],"date-time":"2012-06-13T03:35:59Z","timestamp":1339558559000},"page":"248-256","source":"Crossref","is-referenced-by-count":19,"title":["Treatment of new\u2010onset ulcerative colitis and ulcerative proctitis: a retrospective study"],"prefix":"10.1111","volume":"36","author":[{"given":"J. M.","family":"Richter","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital and Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kushkuley","sequence":"additional","affiliation":[{"name":"Policy Analysis Inc Brookline MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Barrett","sequence":"additional","affiliation":[{"name":"Aptalis Pharma Inc Mont\u2010Saint\u2010Hilaire QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Oster","sequence":"additional","affiliation":[{"name":"Policy Analysis Inc Brookline MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,6,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009735"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.01940.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2010.12.011"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.t01-1-01770.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.727"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001574-200407000-00008"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mib.0000231496.92013.85"},{"key":"e_1_2_6_9_1","first-page":"893","article-title":"The role of mesalamine in the treatment of ulcerative colitis","volume":"3","author":"Karagozian R","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_2_6_10_1","first-page":"1323","article-title":"Ulcerative colitis: diagnosis and treatment","volume":"76","author":"Langan RC","year":"2007","journal-title":"Am Fam Physician"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.04042.x"},{"key":"e_1_2_6_12_1","unstructured":"Health Insurance Portability and Accountability Act of 1996 1320\u2010d2."},{"key":"e_1_2_6_13_1","unstructured":"Public Welfare \u2014 Protection of Human Subjects 45 CFR 46.101."},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-009-1074-z"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32833944bf"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04619.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.04683.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200411000-00006"},{"key":"e_1_2_6_19_1","first-page":"A311","article-title":"Azathioprine, 6\u2010mercaptopurine and thiopurine in inflammatory bowel disease: what is the current clinical practice?","volume":"24","author":"Siriwardana A","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40849.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.08.029"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X10361304"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.04.063"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.05.052"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2012.05175.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2012.05175.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T12:58:25Z","timestamp":1700571505000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2012.05175.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,12]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1111\/j.1365-2036.2012.05175.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2012.05175.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,12]]}}}